CMPX (Compass Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Compass Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-9.16 Mil. Compass Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Compass Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Compass Therapeutics's current FCF Yield % is -16.30%.

The historical rank and industry rank for Compass Therapeutics's FCF Margin % or its related term are showing as below:

CMPX' s FCF Margin % Range Over the Past 10 Years
Min: -5282.24 Med: -5282.24 Max: -5277.06
Current: -5277.06

During the past 7 years, the highest FCF Margin % of Compass Therapeutics was -5277.06%. The lowest was -5282.24%. And the median was -5282.24%.

CMPX's FCF Margin % is ranked worse than
89.1% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs CMPX: -5277.06

Compass Therapeutics FCF Margin % Historical Data

The historical data trend for Compass Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Therapeutics FCF Margin % Chart

Compass Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-5,282.24

Compass Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-1,265.18	-	-

Competitive Comparison of Compass Therapeutics's FCF Margin %

For the Biotechnology subindustry, Compass Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compass Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Compass Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Compass Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-44.899	/	0.85
	=	-5,282.24 %

Compass Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-9.162	/	0
	=	%

Compass Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Compass Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 601, Boston, MA, USA, 02135

Website

https://www.compasstherapeutics.com

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Executives

Richard S Lindahl	director	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Thomas J. Schuetz	director, officer: Chief Executive Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
David M Wurzer	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib	officer: Chief Operating Officer	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau	director	10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled	officer: Chief Scientific Officer	COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016